CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6
Molecular Pain · 2026
DOI: 10.1177/17448069261491583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2026. Verfasst von ZiChao Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Lanzhou University Second Hospital, Lanzhou, Gansu, China. Hauptthemen laut MEDLINE: Migraine Disorders, STAT6 Transcription Factor, Orexin Receptors, Antigens, CD. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lanzhou Science and Technology Plan Project, Second Hospital of Lanzhou University.
Abstract (Originalsprache)
Objective
Chronic migraine (CM) is characterized by central sensitization (CS), in which microglial activation plays a key role. The neuron-glia communication axis CD200/CD200R1 is a critical immunomodulatory pathway. This study investigated whether and how CD200/CD200R1 signaling modulates CS in a CM model.
Methods
A CM mouse model was established by repeated nitroglycerin (NTG) injections. Pain thresholds were assessed. Protein expression in the trigeminal nucleus caudalis (TNC) was analyzed. The role of STAT6 was examined using inhibitor AS1517499.
Results
NTG treatment induced sustained hyperalgesia and downregulated CD200 and CD200R1 expression in the TNC. Administration of the CD200R1 agonist CD200Fc reversed pain hypersensitivity, suppressed the overexpression of CGRP and c-Fos, and reduced pro-inflammatory cytokines. CD200Fc promoted STAT6 phosphorylation and increased expression of anti-inflammatory markers (Arg-1, YM-1, YM-2). Inhibition of STAT6 phosphorylation abolished the therapeutic effects of CD200Fc on pain biomarkers without altering CD200R1 expression.
Conclusion
Our findings demonstrate that enhancing the CD200/CD200R1 pathway alleviates central sensitization and pain hypersensitivity in CM, likely by promoting an anti-inflammatory microglial phenotype via STAT6 phosphorylation. The CD200/CD200R1/STAT6 axis represents a novel therapeutic target for chronic migraine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Lanzhou University Second Hospital, Lanzhou, Gansu, China.
- Foot-and-Mouth Disease and Emerging Diseases Team, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu, China.
ORCID-Profile: ZhaoMing Ge
Förderung
- Lanzhou Science and Technology Plan Project
- Second Hospital of Lanzhou University
Zitieren
APA
Li, Z., Li, D., Fan, Z., Cai, H., & Ge, Z. (2026). CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6. Molecular Pain. https://doi.org/10.1177/17448069261491583
Vancouver
Li Z, Li D, Fan Z, Cai H, Ge Z. CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6. Molecular Pain. 2026. doi:10.1177/17448069261491583
BibTeX
@article{Li2026,
author = {Li, ZiChao and Li, Dan and Fan, ZhenZhen and Cai, HongBin and Ge, ZhaoMing},
title = {CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6},
journal = {Molecular Pain},
year = {2026},
doi = {10.1177/17448069261491583}
}
EUVIMED